Clinical implications of variant ALK FISH rearrangement patterns

Journal of Thoracic Oncology

Volumn 10, Issue 11, 2015, Pages 1648-1652

  Gao, Xin ^a   Sholl, Lynette M ^a   Nishino, Mizuki ^a,b   Heng, Jennifer C ^a,b   Jänne, Pasi A ^a,b   Oxnard, Geoffrey R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Anaplastic lymphoma kinase rearrangement; Crizotinib; Fluorescence in situ hybridization; Non small cell lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; EXON; FALSE POSITIVE RESULT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; SMOKING; TUMOR VOLUME; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; YOUNG ADULT;

EID: 84945292816     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000665     Document Type: Article

References (19)

1. Inamura K, Takeuchi K, Togashi Y, EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008 3 13 17
2. Wong DW, Leung EL, So KK, University of Hong Kong Lung Cancer Study Group The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-Type EGFR and KRAS. Cancer 2009 115 1723 1733
3. Shaw AT, Yeap BY, Mino-Kenudson M, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009 27 4247 4253
4. Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 363 1693 1703
5. Shaw AT, Kim DW, Nakagawa K, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013 368 2385 2394
6. Camidge DR, Kono SA, Flacco A, Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010 16 5581 5590
7. Sholl LM, Weremowicz S, Gray SW, Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013 8 322 328
8. Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009 45 228 247
9. Subbiah V, McMahon C, Patel S, STUMP un"stumped": Anti-Tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol 2015 8 66
10. Dai Z, Kelly JC, Meloni-Ehrig A, Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas. Mol Cytogenet 2012 5 44
11. Camidge DR, Theodoro M, Maxson DA, Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 2012 118 4486 4494
12. McLeer-Florin A, Moro-Sibilot D, Melis A, Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: A French study. J Thorac Oncol 2012 7 348 354
13. Cutz JC, Craddock KJ, Torlakovic E, Canadian anaplastic lymphoma kinase study: A model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol 2014 9 1255 1263
14. Wu YC, Chang IC, Wang CL, Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One 2013 8 e70839
15. Gainor JF, Varghese AM, Ou SH, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: An analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013 19 4273 4281
16. Sholl LM, Aisner DL, Varella-Garcia M, LCMC Investigators Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol 2015 10 768 777
17. Lindeman NI, Cagle PT, Beasley MB, Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013 8 823 859
18. Bergethon K, Shaw AT, Ou SH, ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012 30 863 870
19. Wang R, Hu H, Pan Y, RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012 30 4352 4359